Radiochemotherapy of esophageal cancer

Journal of Thoracic Oncology

Volumn 2, Issue 6, 2007, Pages 553-568

  Liao, Zhongxing ^a,b   Cox, James D ^a   Komaki, Ritsuko ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adverse effect; Esophageal neoplasm; Esophagectomy; Prognostic factors; Radiochemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELIAC ARTERY; CLINICAL TRIAL; DISEASE SEVERITY; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; LUNG COMPLICATION; LYMPH NODE METASTASIS; METABOLISM; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERICARDITIS; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH PROBLEM; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; BRACHYTHERAPY; ESOPHAGUS TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 34447118186     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000275339.62831.5e     Document Type: Review

References (121)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
2. Finley RJ. Invited commentary. J Am Coll Surg 2000;190:572-573.
3. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society, 2006.
4. Daly J, Fry W, Little A, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190:562-573.
5. Patti M, Li R, Tedesco P, et al. Esophageal cancer. e-Medicine. Vol. 2006: 2005. Available at: www.emedicine.com/MED?topic741, htm.
6. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: Cancer Incidence, Mortality, and Prevalence Worldwide. IARC Cancer Base. Lyon, France: IARC Press, 2002.
7. Devesa S, Blot W, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
8. Dulai GS, Guha S, Kahn KL, et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
9. DeMeester T. Esophageal carcinoma: current controversies. Semin Surg Oncol 1997;13:217-233.
10. Wong R, Malthaner R. Esophageal cancer: a systematic review. Curr Probl Cancer 2000;24:373-373.
11. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
12. van Westreenen HL, Westerterp M, Bossuyt PMM, et al. Systematic review of the staging performance of 18f-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004;22:3805-3812.
13. Schneider P, Baldus S, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005;242:684-692.
14. Denham JW, Steigler A, Kilmurray J, et al. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol 2003;15:98-108.
15. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg 2003;125:1103-1113.
16. Kunisaki C, Akiyama H, Nomura M, et al. Developing an appropriate staging system for esophageal carcinoma. J A Coll Surg 2005;201:884-890.
17. Malaisrie S, Hofstetter W, Correa A, et al. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2006;131:65-72.
18. Gu Y, Swisher S, Ajani J, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 2006;106:1017-1025.
19. Swisher S, Maish M, Erasmus J, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-1160.
20. Mariette C, Taillier G, Van Seuningen I, et al. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004;78:1177-1183.
21. Swisher S, Hofstetter W, Wu T, et al. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg 2005;241:810-817; discussion.
22. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317.
23. Christie N, Rice T, DeCamp M, et al. M1a/M1b esophageal carcinoma: clinical relevance. J Thorac Cardiovasc Surg 1999;118:900-907.
24. Eloubeidi M, Wallace M, Hoffman B, et al. Predictors of survival for esophageal cancer patients with and without celiac axis lymphadenopathy: impact of staging endosonography. Ann Thorac Surg 2001;72:212-120.
25. Catalano M, Alcocer E, Chak A, et al. Evaluation of metastatic celiac axis lymph nodes in patients with esophageal carcinoma: accuracy of EUS. Gastrointest Endosc 1999;50:352-356.
26. Stahl M, Hansjochen W, Martin S, et al. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005;V131:67-72.
27. Geh J, Crellin A, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in esophageal cancer. Br J Surg 2001;88:338-356.
28. Hennequin C, Gayet B, Sauvanet A, et al. Impact on survival of surgery after concomitant chemoradiotherapy for locally advanced cancers of the esophagus. Int J Radiat Oncol Biol Phys 2001;49:657-664.
29. Kelsen D, Iison D, Minsky B, et al. Phase I trial of combined modality therapy for localized esophageal cancer: radiation therapy concurrent cisplatin and escalating doses of 96 hour infusional paclitaxel. Proc Am Soc Clin Oncol 1998;17:260a (abstr).
30. Hoffman PC, Haraf DJ, Ferguson MK, et al. Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis. Ann Oncol 1998;9:647-651.
31. Luketich J, Nguyen N, Ramanathan R, et al. Induction and postoperative chemotherapy with paclitaxel, 5-fluorouracil and cisplatin regimen for carcinoma of the esophagus. Program/Proceedings American Society of Clinical Oncology 1998;17:295a.
32. Lynch T, Choi N, Wright M, et al. A phase I/II trial of preoperative taxol (t), 5-FU (f) and concurrent boost radiation (XRT) in esophageal cancer. Program/Proceedings American Society of Clinical Oncology 1997;16:261a.
33. Meluch A, Hainsworth J, Gray J, et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999;5:84-91.
34. Weiner L, Colarusso P, Goldberg M, et al. Combined modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 1997;24:S19-93-S19-95.
35. Swisher S, Ajani J, Komaki R, et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2003;57:120-127.
36. Stahl M, Wilke H, Fink U, et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: interim analysis of a phase III trial. J Clin Oncol 1996;14:829-837.
37. Ganem G, Dubray B, Raoul Y, et al. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus. J Clin Oncol 1997;15:701-711.
38. Forastiere A, Heitmiller R, Lee D, et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 1997;3:144-152.
39. Heath E, Burtness B, Heitmiller R, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-876.
40. Chirieac L, Swisher S, Ajani J, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2005;103:1347-1355.
41. Walsh T, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467.
42. Urba S, Orringer M, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-313.
43. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-668.
44. Flamen P, Lerut A, Van Cutsem E, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-3210.
45. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133-1136.
46. Hong D, Lunagomez S, Kim E, et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 2005;104:1620-1626.
47. Swisher S, Erasmus J, Maish M, et al. 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004;101:1776-1785.
48. Downey R, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:429-432.
49. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-368.
50. Brun E, Kjellen E, Tennval J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-135.
51. Weber W, Ziegler S, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-1777.
52. Weber W, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-2657.
53. Ott K, Weber W, Fink U, et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg 2003;27:1035-1039.
54. Wieder H, Brucher B, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-908.
55. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
56. Al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-284.
57. Cooper J, Guo M, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
58. Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598.
59. Smith T, Ryan L, Douglass HJ, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:269-276.
60. Araujo C, Souhami L, Gil R, et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991;67:2258-2261.
61. Roussel A, Jacob J, Haegele P, et al. Controlled clinical trial for the treatment of patients with inoperable esophageal carcinoma: a study of EORTC Gastrointestinal Tract Cancer Cooperative Group. Recent Results Cancer Res 1988;110:21-29.
62. Slabber C, Nel J, Schoeman L, et al. A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus. Am J Clin Oncol 1998;21:462-465.
63. Withers HR, Peters LJ. Basic principles of radiotherapy: basic clinical parameters. In Fletcher GA (Ed.). Textbook of Radiotherapy, 3rd ed. Philadelphia: Lea & Febiger; 1980. P. 180.
64. Coia L, Engstrom P, Paul A. Long term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal cancer. Int J Radiat Oncol Biol Phys 1991;20:29-36.
65. John M, Flam M, Mowry P, et al. Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation. Cancer 1989;63:2397-2403.
66. Minsky B, Pajak T, Ginsberg R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174.
67. Zhang Z, Liao Z, Jin J, et al. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005;61:656-664.
68. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-2174.
69. Liao Z, Zhang Z, Jin J, et al. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 2004;60:1484-1493.
70. Coia LR, Minsky BD, Berkey BA, et al. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 2000;18:455-462.
71. Bedenne L, Michel P, Bouche O, et al. Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102) (abstract). Proceedings of American Society of Clinical Oncology 2002:130.
72. Kelsen D, Ginsberg R, Pajak T, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
73. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128-1137.
74. Rohatgi P, Swisher S, Correa A, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer 2006;106:552-558.
75. Hulscher JBF, van Sandick JW, de Boer AGEM, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669.
76. Siewert J, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353-361.
77. MRC, Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733.
78. Hofstetter W, Swisher S, Correa A, et al. Treatment outcome of resected esophageal cancer. Ann Surg 2002;236:1-10.
79. Urba S, Orringer M, Perez-Tamayo C, et al. Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer 1992;69:285-291.
80. Forastiere A, Orringer M, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol 1993;11:1118-1123.
81. Keller S, Ryan L, Coia L, et al. High dose chemoradiotherapy followed by esophagectomy for adenocarcinoma of the esophagus and gastroesophageal junction: results of a phase II study of the Eastern Cooperative Oncology Group. Cancer 1998;83:1908-1916.
82. Choi N, Park S, Lynch T, et al. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Int J Radiat Oncol Biol Phys 2004;60:111-122.
83. Kleinberg L, Knisely J, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003;60:427-436.
84. Adelstein D, Rice T, Rybicki L, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000;18:2032-2039.
85. Meluch A, Greco F, Gray J, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: Final results of a Minnie Pearl Cancer Research Network phase II trial Cancer J 2003;9:251-260.
86. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987;5:622-628.
87. Naunheim K, Petruska P, Roy T, et al. Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 1992;103:887-893.
88. Chiappori A, DeVore R, Stewart J, et al. Phase II study of neo-adjuvant cisplatin (P), 5-FU, leucovorin (LV), etoposide (E) & concurrent radiotherapy (RT) in patients with esophageal cancer. J Clin Oncol 1996;15:214.-
89. Hoff S, Stewart J, Sawyers J, et al. Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. Ann Thorac Surg 1993;56:282-286.
90. Bates B, Detterbeck F, Bernard S, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996;14:156-163.
91. Blanke C, Chiappori A, Epstein B. A phase II trial of neoadjuvant paclitaxel (T) and cisplatin (P) with radiotherapy, followed by surgery (S) and postoperative T with 5-fluorouracil (F) and leucovorin (L) in patients (pts) with locally advanced esophageal cancer (LAEC) (abstract). J Clin Oncol 1997;16:283.
92. Bedenne L, Seitz J, Milan C, et al. Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study. Gastroenterol Clin Biol 1998;22:273-281.
93. Urba S, Orringer M, Iannettoni M. A phase II trial of preoperative cisplatin, paclitaxel, and radiation therapy XRT before trans-hiatal esophagectomy (THE) in patients (pts) with locoregional esophageal cancer (CA) J Clin Oncol 2000;19:248a.
94. Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001;19:1-7.
95. Nygaard K, Hagen S, Hansen H, et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The Second Scandinavian Trial in Esophageal Cancer. World J Surg 1992;16:1104-1110.
96. Le Prise E, Etienne P, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994;73:1779-1784.
97. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-393.
98. Bosset J, Gignoux M, Triboulet J, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
99. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210-217.
100. Bosset J, Lorchel F, Mantion G, et al. Radiation and chemoradiation therapy for esophageal adenocarcinoma. J Surg Oncol 2005;92:239-245.
101. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-761.
102. Urschel J, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-543.
103. Ajani J, Komaki R, Putnam J, et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001;92:279-286.
104. Jin J, Liao Z, Zhang Z, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004;60:427-436.
105. Komaki R, Janjan N, Ajani J, et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology 2000;14:34-37.
106. Ajani J, Walsh G, Komaki R, et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004;100:2347-2354.
107. Bains M, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002;124:270-277.
108. Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003;21:2926-2932.
109. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005;16:1133-1139.
110. Bosset J, Horiot J. Pre-operative chemoradiotherapy and total mesorectal excision surgery of rectal cancer: towards the eradication of pelvic failures? Aust N Z J Surg. 1999;69:622-624.
111. Law S, Wong K, Kwok K, et al. Predictive factors for postoperative pulmonary complications and mortality after esophagectomy for cancer. Ann Surg 2004;240:791-800.
112. Fang W, Kato H, Tachimori Y, et al. Analysis of pulmonary complications after three-field lymph node dissection for esophageal cancer. Ann Thorac Surg 2003;76:903-908.
113. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-930.
114. Lee H, Vaporciyan A, Cox J, et al. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys 2003;57:1317-1322.
115. CDC. Definitions for nosocomial infections. Am Rev Respir Dis 1989; 139:1058-1059.
116. Wang S, Liao Z, Vaporciyan A, et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006;64:692-699.
117. Tucker SL, Liu HH, Wang S, et al. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2006;66:754-761.
118. Wang S, Liao ZX, Wei X, et al. Association between induction chemotherapy and increased risk of treatment related pneumonitis in esophageal cancer patients treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2006;66:S261-S262.
119. Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 2000;9:1381-1385.
120. Liu H, Blackmon S, Gayed I, et al. Cardiac toxicity from chemoradiation with or without surgery for patients with esophageal cancers. Int J Radiat Oncol Biol Phys 2006;66:s284-s285.
121. Gayed I, Liu H, Wei X, et al. The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. J Nucl Med 2006;47:1756-1762.